LONDON, Feb 9 (Reuters) – Britain’s business climate is deterring biopharma companies from investing in the country, AstraZeneca (AZN.L) chief Pascal Soriot said on Thursday, highlighting his company’s decision to shift plans for a new manufacturing plant to Ireland. The UK government’s ambition to become a life sciences "superpower" has been hampered by a discouraging tax environment, Soriot said, acknowledging the country was grappling with an "explosion of costs" driven by the impact of the COVID-19 on the healthcare system. While Britain is already considered a research powerhouse it is also lacking in other areas such as manufacturing incentives, and access to green energy, he said during a news conference after the company’s results. Without those elements, he added, companies will seek to develop drugs in other markets "where you know you’re going to get access and you’re going to get a price that can justify the investment". The British drugmaker seeks to offset declining sales of COVID-19 medicines with its cancer, metabolic and rare disease drugs and Soriot said it is on track to deliver at least 15 new medicines this decade. He highlighted AstraZeneca’s recent decision to build a manufacturing facility in Ireland instead of the UK […]
